BAX or LMAT: Which Is the Better Value Stock Right Now?
Investors looking for stocks in the Medical - Products sector might want to consider either Baxter International (BAX) or LeMaitre Vascular (LMAT). But which of these two companies is the best option for those looking for undervalued stocks?
Should Value Investors Buy Baxter International (BAX) Stock?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Baxter to import 18,000 tons of IV products to US by year-end
Baxter International said on Thursday it will import 18,000 tons of intravenous products from its newly cleared international plants to the U.S. by the end of the year to mitigate a shortage caused by Hurricane Helene.
Baxter Is A Strong Buy: The Turnaround Story You Can't Ignore
The Federal Reserve's rate cut historically boosts healthcare stocks, and Baxter International's recent downturn presents a buying opportunity due to overblown market reactions. Baxter's acquisition of Hill-Rom and subsequent challenges, including rising input costs and supply chain issues, have been addressed, setting the stage for recovery. The sale of Baxter's kidney care business and debt repayment will strengthen the balance sheet, enabling future share repurchases and margin expansion.
Reasons to Add Baxter International Stock to Your Portfolio Now
BAX's robust growth across all regions, along with transformational initiatives, boosts confidence. However, pandemic-related disruption continues to hurt sales.
Here's Why Baxter International (BAX) is a Strong Value Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
BAX vs. LMAT: Which Stock Is the Better Value Option?
Investors looking for stocks in the Medical - Products sector might want to consider either Baxter International (BAX) or LeMaitre Vascular (LMAT). But which of these two stocks presents investors with the better value opportunity right now?
Are Investors Undervaluing Baxter International (BAX) Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Does Baxter Stock Offer Any Room For Growth?
Baxter stock (NYSE: BAX), a healthcare company, currently trades at $38 per share, more than 50% lower than the level seen in February 2022. BAX stock has fared worse than its peer – Becton, Dickinson & Company stock, down 7% over this period.
Baxter Shares May Gain on the Launch of Its Latest Vest APX System
BAX launches its next-generation airway clearance system, The Vest APX System, for chronic lung conditions.
4 Medical Product Stocks to Buy From a Prospective Industry
Ongoing rise in demand for medical procedures and cost-cutting initiatives should support the Zacks Medical-Products industry. BSX, BAX, HAE and PAHC are well-poised to gain from the favorable factors.
5 Incredible Healthcare High-Yield Blue-Chip Bargain Buys For 2025
Healthcare is undervalued despite being the top sector for earnings growth, making it an attractive investment with solid fundamentals and the potential for explosive returns in 2025. Investing in healthcare ETFs or individual undervalued healthcare stocks can capitalize on the sector's recovery and expected double-digit growth through 2026. Screening for blue-chip healthcare stocks with solid fundamentals and fair valuations can yield superior returns, including these five coiled spring blue chips.
